Viking Therapeutics to Present at Key Investor Conferences Amid Critical Clinical Trials
Event summary
- Viking Therapeutics will participate in the Leerink Partners Global Healthcare Conference 2026 and the Jefferies Biotech on the Beach Summit in Miami, FL, with a fireside chat scheduled for March 10, 2026.
- The company is advancing its Phase 3 obesity program for VK2735, including two trials (VANQUISH-1 and VANQUISH-2).
- VK2809 achieved primary and secondary endpoints in a Phase 2b NASH study and demonstrated significant LDL-C and liver fat reductions in a Phase 2a NAFLD trial.
- Viking is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD), showing safety and efficacy in a Phase 1b trial.
The big picture
Viking Therapeutics is positioning itself as a key player in the metabolic and endocrine disorders space, with multiple clinical programs in advanced stages. The company's participation in high-profile investor conferences underscores its focus on engaging with the investment community amid critical clinical milestones. The success of its lead candidates, particularly in obesity and NASH, could drive significant market opportunities.
What we're watching
- Clinical Trial Progress
- The outcome of the Phase 3 VANQUISH trials for VK2735 will be critical in determining its market potential in obesity treatment.
- Regulatory Pathways
- The pace at which VK2809 advances through Phase 3 trials for NASH and NAFLD will impact its commercialization timeline.
- Investor Sentiment
- How Viking Therapeutics' presentations at these conferences influence investor confidence and stock performance.
Related topics